Table 3.
Meta-analysis of oncological outcomes
| Outcome of interest |
No. of studies |
Sample size |
Heterogeneity |
Model | Overall effect size | 95%CI of overall effect | P-value | ||
| TLPD | OPD | P | I2 | ||||||
| Tumor size | 10 | 814 | 4782 | < 0.00001 | 85% | R | WMD = -0.32 | -0.58, -0.07 | 0.01 |
| RLNs | 12 | 1600 | 12347 | < 0.00001 | 77% | R | WMD = 1.32 | 0.57, 2.06 | 0.0005 |
| R0 rate | 19 | 1991 | 14477 | 0.88 | 0 | F | OR = 1.28 | 1.13, 1.44 | 0.0001 |
| Time to adjuvant chemotherapy | 2 | 867 | 7526 | 0.39 | 0 | F | WMD = -2.44 | -4.39, -0.49 | 0.01 |
| RFS of all malignant tumor patients | |||||||||
| 1-yr RFS | 2 | 52 | 37 | NA | NA | F | OR = 0.44 | 0.16, 1.23 | 0.12 |
| 3-yr RFS | 2 | 52 | 37 | 0.22 | 35% | F | OR = 0.53 | 0.19, 1.47 | 0.22 |
| 5-yr RFS | 2 | 52 | 37 | 0.31 | 4% | F | OR = 0.40 | 0.12, 1.33 | 0.14 |
| OS of all malignant tumor patients | |||||||||
| 1-yr OS | 5 | 412 | 2206 | 0.007 | 72% | R | OR = 0.62 | 0.33, 1.19 | 0.15 |
| 2-yr OS | 4 | 400 | 2194 | 0.03 | 66% | R | OR = 0.61 | 0.32, 1.17 | 0.14 |
| 3-yr OS | 5 | 412 | 2206 | 0.08 | 51% | R | OR = 0.80 | 0.40, 1.62 | 0.54 |
| 4-yr OS | 4 | 400 | 2194 | 0.60 | 0 | F | OR = 0.73 | 0.41, 1.30 | 0.28 |
| 5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
| OS of PDAC patients | |||||||||
| 1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
| 2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
| 3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
| 4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
| 5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
| OS of periampullary adenocarcinoma patients | |||||||||
| 1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
| 2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
| 3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
| 4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
| 5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
| 5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
RLNs: Retrieved lymph nodes; RFS: Recurrence-free survival; OS: Overall survival; PDAC: Pancreatic ductal adenocarcinoma; OR: Odds Ratio; CI: Confidence interval; F: Fixed-effects model; R: Random-effects model; NA: Not applicable; TLPD: Total laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.